Patents by Inventor Chandrasekar Venkataramani

Chandrasekar Venkataramani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20240124412
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 18, 2024
    Inventors: Gayatri Balan, Peter A. Blomgren, Julian A. Codelli, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Combination MCL-1 inhibitors with anti-cancer agents
    Patent number: 11957693
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: April 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • IKAROS zinc finger family degraders and uses thereof
    Patent number: 11897862
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20240002367
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 24, 2023
    Publication date: January 4, 2024
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230373950
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: November 23, 2023
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • MCL1 INHIBITORS
    Publication number: 20230348494
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 2, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
  • MCL-1 INHIBITORS
    Publication number: 20230312490
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 5, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230295111
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 21, 2023
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230242508
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • LPA receptor antagonists and uses thereof
    Patent number: 11702407
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
  • TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230212149
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: December 5, 2022
    Publication date: July 6, 2023
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230212151
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • LPA receptor antagonists and uses thereof
    Patent number: 11584738
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTS
    Publication number: 20230015985
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Application
    Filed: June 9, 2022
    Publication date: January 19, 2023
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230012262
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: May 13, 2021
    Publication date: January 12, 2023
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
    Patent number: 11548871
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220411406
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: May 11, 2022
    Publication date: December 29, 2022
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska